Century Therapeutics Files 8-K on Financials

Ticker: IPSC · Form: 8-K · Filed: May 15, 2025 · CIK: 1850119

Sentiment: neutral

Topics: financial-condition, operations, disclosure

TL;DR

Century Therapeutics dropped an 8-K detailing its financial condition and operations.

AI Summary

Century Therapeutics, Inc. filed an 8-K on May 15, 2025, reporting on its results of operations and financial condition. The filing also includes Regulation FD disclosures and financial statements and exhibits. The company is incorporated in Delaware and its principal executive offices are located in Philadelphia, Pennsylvania.

Why It Matters

This 8-K filing provides investors with crucial updates on Century Therapeutics' financial performance and operational status, impacting investment decisions.

Risk Assessment

Risk Level: low — This filing is a routine disclosure of financial information and does not indicate any immediate or significant risks.

Key Players & Entities

FAQ

What specific financial results are being reported in this 8-K?

The filing indicates it reports on 'Results of Operations and Financial Condition' but does not provide specific figures within the provided text.

Are there any new material agreements or events disclosed?

The filing mentions 'Regulation FD Disclosure' and 'Financial Statements and Exhibits,' suggesting potential disclosures, but specific details are not in the provided text.

What is the SIC code for Century Therapeutics, Inc.?

The SIC code for Century Therapeutics, Inc. is 2836, categorized under 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)'.

When was Century Therapeutics, Inc. incorporated?

Century Therapeutics, Inc. was incorporated in Delaware.

What is the primary business address of Century Therapeutics, Inc.?

The primary business address is 25 North 38th Street, 11th Floor, Philadelphia, Pennsylvania, 19104.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on May 15, 2025 regarding Century Therapeutics, Inc. (IPSC).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing